RENK and QinetiQ announce strategic partnership in the field of advanced mobility technology - The companies will collaborate on future mobility concepts for military land platforms from 5 to 60 tons - Focus on hybridization concepts and uncrewed ground vehicles Augsburg, September 10, 2024 – RENK ...
Capital Markets Day 2024: RENK Group AG aims to double group revenue in the medium term - Group revenue expected to increase to around € 2 billion in the medium term; additional growth planned through strategic M&A activities - Growing global defense spending offers significant growth potential, ...
Leipzig Tourismus und Marketing GmbH
H1 2024 results: RENK Group AG continues successful business development with record figures – more precisely defined financial guidance at upper end of the forecast range - H1 revenue increase to € 510 million (H1 2023: € 410 million) – ...
Change in the Executive Board of RENK Group AG - Christian Schulz, CFO of RENK Group AG, resigns from office with effect from September 30, 2024 in agreement with the Supervisory Board - Anja Mänz-Siebje, Head of Corporate Finance and CFO of RENK GmbH, has been appointed Chief Financial and IT Officer of RENK Group AG as of October 1, 2024 Augsburg, ...
RENK signs development contract with leading European systems house for land forces Villepinte / Frankreich, 20. Juni 2024 – RENK, a leading provider of vehicle mobility solutions, is pleased to announce the signing of a development contract with one of the leading European systems houses for land ...
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
